Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Preferred Shares (2020 - 2026)

Cogent Biosciences' Preferred Shares history spans 7 years, with the latest figure at $35.6 million for Q1 2026.

  • Quarterly Preferred Shares fell 34.25% to $35.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $35.6 million through Mar 2026, down 34.25% year-over-year, with the annual reading at $53.8 million for FY2025, 4.75% down from the prior year.
  • Preferred Shares came in at $35.6 million for Q1 2026, down from $53.8 million in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $78.4 million in Q1 2022 to a low of $35.6 million in Q1 2026.
  • The 5-year median for Preferred Shares is $60.0 million (2023), against an average of $59.1 million.
  • Year-over-year, Preferred Shares changed 0.0% in 2025 and then crashed 34.25% in 2026.
  • Cogent Biosciences' Preferred Shares stood at $65.8 million in 2022, then dropped by 8.8% to $60.0 million in 2023, then fell by 5.86% to $56.5 million in 2024, then dropped by 4.75% to $53.8 million in 2025, then crashed by 33.93% to $35.6 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Preferred Shares are $35.6 million (Q1 2026), $53.8 million (Q4 2025), and $54.1 million (Q3 2025).